蒽环类药物心脏毒性早期检测研究进展  

Advances in the Early Detection of Anthracycline-associated Cardiotoxicity

作　　者：但敏 姜永生 Dan Min;Jiang Yongsheng(Department of Oncology,Tongji Hospital,Tongji Medical College,Huashong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤科,武汉430030

出　　处：《华中科技大学学报(医学版)》2025年第2期267-274,共8页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：湖北陈孝平科技发展基金会菁锐发展基金资助项目(No.CXPJJH122006-1026)。

摘　　要：蒽环类药物作为一种广谱抗肿瘤药物,在乳腺癌、淋巴瘤、软组织肿瘤等多种恶性肿瘤的治疗过程中发挥着重要作用。然而,其显著的心脏毒性不仅限制了该药物的临床应用,而且对患者的生活质量及远期预后也有很大影响。近年来,随着检测技术的不断进步,蒽环类药物所致心脏毒性的检测方法也在不断更新与发展。该文主要就目前已开展的关于蒽环类药物心脏毒性的检测方法进行综述,以期为蒽环类药物所致心脏毒性的早期发现及临床早期干预提供重要信息,降低肿瘤患者发生严重心脏损伤的风险。Anthracyclines(ANT),serving as a broad-spectrum antitumor medication,play a pivotal role in the treatment of various malignant tumors such as breast cancer,lymphoma,and soft tissue tumors.Nevertheless,their profound cardiotoxicity not only imposes limitations on the clinical application of these drugs,but also has significant impacts on patients'quality of life and long-term prognosis.In recent years,with the continuous advancement of detection technology,methods for detecting anthracycline-induced cardiotoxicity have been constantly updated and developed.This review mainly aims to provide crucial insights into current methods for detecting anthracycline-induced cardiotoxicity in order to facilitate early detection and clinical management while reducing the risk of severe cardiac injury in cancer patients.

关 键 词：蒽环类药物 心脏毒性 早期检测 

分 类 号：R730.53[医药卫生—肿瘤]